Introduction {#H1-1-ZOI190097}
============

There is an increasing body of evidence that different pesticides or residues used in agricultural occupations are a risk factor for non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL). Occupational exposure has been reported to be associated with a higher rate of NHL in several meta-analyses^[@zoi190097r1],[@zoi190097r2],[@zoi190097r3],[@zoi190097r4],[@zoi190097r5]^ and prospective studies.^[@zoi190097r6],[@zoi190097r7]^ More recently, a prospective study^[@zoi190097r8]^ showed an association of a higher frequency of organic food intake with decreasing risk of NHL. Three agents have been associated with NHL and classified as carcinogenic by the International Agency for Research on Cancer: glyphosate, malathion, and diazinon.^[@zoi190097r9]^ Fungicides, insecticides, or herbicides are widely used for farming; their cumulated toxic effects, called the *cocktail effect*, are not well characterized and may induce specific carcinogenic pathways.^[@zoi190097r10]^

Diffuse large B-cell lymphoma accounts for approximately 30%^[@zoi190097r11]^ of NHL, characterized by an aggressive presentation. In a prospective study,^[@zoi190097r6]^ the relative standardized incidence ratio for DLBCL among farmers using pesticides was 1.3 (95% CI, 1.0-1.6) and 1.5 (95% CI, 1.1-2.1) in spouses. Little is known about pesticide-related DLBCL regarding clinical and pathologic characteristics and prognosis. Treatment of DLBCL is anthracycline-based chemotherapy combined with an anti-CD20 monoclonal antibody, allowing a high rate of complete response (2-year progression-free survival of 69% and 2-year overall survival \[OS\] of 78%).^[@zoi190097r12]^ The outcome for primary refractory or early relapsing DLBCL is poor: 20% of patients are alive after 2 years according to a recent retrospective study.^[@zoi190097r13]^

Genotoxicity and reactive oxygen species generation in healthy cells and cancer cells are common mechanisms of action shared by different pesticides used for agricultural production and chemotherapy. They are involved in the transformation of healthy lymphocytes into clonal ones after different pesticide exposure.^[@zoi190097r14],[@zoi190097r15]^ Adaptation of different cell systems after different pesticide exposure could lead to DNA repair and antioxidant mechanisms. These mechanisms represent a significant pathway for chemotherapy resistance: a DNA repair score was correlated significantly with outcome after chemotherapy for DLBCL.^[@zoi190097r16]^ Another study^[@zoi190097r17]^ found an association between response to chemotherapy and antioxidant pathways in lymphoid malignant tumors, and one study^[@zoi190097r18]^ found resistance of lymphoma cells to cytotoxic treatment after paraquat exposure.

We hypothesized that cellular adaptation to damage induced by long-term occupational pesticide exposure, promoting DNA repair pathways and antioxidant defenses, hinders chemotherapy efficiency. The aim of this study was to examine the association between occupational exposure to pesticides among patients treated for DLBCL and immunochemotherapy response and survival.

Methods {#H1-2-ZOI190097}
=======

Study Design {#H2-1-ZOI190097}
------------

A retrospective, multicenter cohort of adults with DLBCL receiving first-line immunochemotherapy was performed. Comparison of patients exposed to pesticides for professional activity with nonexposed patients was performed. This report followed the Strengthening the Reporting of Observational Studies in Epidemiology ([STROBE](http://www.equator-network.org/reporting-guidelines/strobe/)) reporting guideline. Ethical and regulatory approvals were obtained from the French Data Protection Committees (Advisory Committee on Information Processing in Material Research in the Field of Health and National Commission for Computing and Liberties). No informed consent was required but oral information was given to the patients or their proxies. Data were deidentified when collected.

Setting {#H2-2-ZOI190097}
-------

All patients treated for DLBCL from January 1, 2010, and July 15, 2015, in the 6 hematology departments of Languedoc-Roussillon, France (2 university hospitals, 1 private hospital, and 3 general hospitals) were considered for inclusion. Analysis of the data was performed from July 1, 2017, to July 15, 2018.

Participants {#H2-3-ZOI190097}
------------

Patients older than 18 years with DLBCL receiving standardized first-line treatment were eligible for inclusion. We performed a systematic review of the national prospective payment system files of patients with non-Hodgkin nonfollicular lymphoma. Inclusion criteria were histopathologic diagnosis of DLBCL and anthracycline-based and anti-CD20--based first-line therapy. Exclusion criteria were tutorship, risk factors linked to immune dysfunction (ie, HIV infection, hepatitis C virus infection, rheumatoid arthritis, systemic lupus erythematous, Sjögren syndrome, psoriasis, celiac disease, and common variable immunodeficiency), primary central nervous system lymphoma, leg-type B-cell lymphoma, lymphomatoid granulomatosis, DLBCL related to inflammation or transplantation, plasmablastic lymphoma, primary effusion lymphoma, Castleman disease--associated DLBCL, double-hit lymphoma, and unclassified lymphoma. Contact with patients or their proxies was made by telephone, and definitive inclusion was made after patient or proxy agreement and survey completion. Patients from Montpellier University Hospital were the first recruited, and the yearly rate of unreachable patients was used to adjust the period of preselection for the other centers to include the necessary number of participants required for the study. Clinical data for outcomes were collected at least 2 years after diagnosis. Vital status of patients unavailable to follow-up was investigated on the civil register.

Diagnostic Criteria {#H2-4-ZOI190097}
-------------------

Histopathologic criteria for DLBCL are defined in the World Health Organization 2008 classification of lymphoid neoplasm.^[@zoi190097r11]^ Complete clinical, biological, and imagery-related diagnostic criteria, as well as response and follow-up, were retrieved from patient files.

Outcomes {#H2-5-ZOI190097}
--------

The primary outcome was response to treatment assessed by local investigators after 4 cycles of immunochemotherapy, clinical evaluation, and positron emission tomography or computed tomography if not available. Treatment failure was defined as absence of complete response according to the 2014 Lugano criteria.^[@zoi190097r19]^ Treatment discontinued because of toxic effects was classified as treatment failure. Secondary outcomes were event-free survival (EFS), defined as the absence of progressive disease during treatment, disease activity after 4 cycles of treatment, relapse, or toxicity-related death, and OS was defined as the absence of death within the 2 years after diagnosis.

Pesticide Exposures {#H2-6-ZOI190097}
-------------------

Data on job positions held longer than 1 year were collected. The corresponding codes according to French classification for socioeconomic position^[@zoi190097r20]^ and economic activities^[@zoi190097r21]^ were inputted into the French job exposure matrix (JEM) PESTIPOP^[@zoi190097r22]^ to assess the likelihood of pesticide exposure and its reliability (eAppendix in the [Supplement](#note-ZOI190097-1-s){ref-type="supplementary-material"}). Source of exposure was classified into 4 occupational groups: agriculture (eg, vineyard workers), green spaces (eg, gardeners), woodwork (eg, carpenters), and public hygiene (eg, pest control workers) (patients could be placed into \>1 group). Occupational pesticide exposure was considered in 4 different ways. The first categorization considered all probabilities of exposure. The second one considered only exposing agricultural occupations. The third one considered only high probability of exposure (\>75%), as defined by the PESTIPOP matrix generation. The fourth considered high probability of exposure (\>75%) and high reliability as defined by the PESTIPOP matrix generation.

Potential Confounders and Other Prognostic Factors {#H2-7-ZOI190097}
--------------------------------------------------

Prognostic factors were recorded from patient files for multivariate analysis: age, European Cooperative Oncology Group score, lactate dehydrogenase level, Ann Arbor stage, extranodal disease (combined with the International Prognostic Index \[IPI\]),^[@zoi190097r23]^ bulky disease (tumor size \>10 cm), prior tumor treated with chemotherapy or radiotherapy, transformation from low-grade lymphoma, treatment in a teaching hospital, marital status, and travel time to hospital less than 15 minutes, according to categories defined by Le Guyader-Peyrou.^[@zoi190097r24]^ The distance between health care centers and home was computed on the basis of Open Street Resource Map geographic data^[@zoi190097r25]^ and using an R package interface rCarto (R Foundation).^[@zoi190097r26]^

Data Source and Measurement {#H2-8-ZOI190097}
---------------------------

A single investigator (S.L.) collected clinical data and outcomes from patient files in hospitals at least 2 years after diagnosis. A clinical research assistant (Q.A.) performed data collection of occupational history in 3 steps: (1) informing patients or relatives of the study purpose by telephone, (2) mailing a survey for occupational history, and (3) data collection during the second telephone interview. For each job, data collected were job title, description of tasks, and periods of work. Job titles were encoded according to the French classifications.^[@zoi190097r20],[@zoi190097r21]^ The anonymized encoded job data were sent to an independent epidemiologic team, who performed computational analysis using JEM masked for all patient information.

Bias {#H2-9-ZOI190097}
----

Selection bias was limited by prescreening all patients treated for lymphoma in the 6 hospitals. Differential classification bias was limited through 2 masking levels. Investigation for occupational history was performed masked for primary outcome but not for OS because of telephone contact with patients or proxies. Classification for exposure to pesticides was performed masked for all outcomes by an independent team. Bias attributable to confounding was controlled using a multivariate model for statistical analysis, with all independent prognostic factors described in the literature^[@zoi190097r23],[@zoi190097r24]^ and potential confounding factors highlighted by univariate analysis.

Study Size {#H2-10-ZOI190097}
----------

According to a prospective cohort of patients with hematologic disorder conducted at Montpellier University Hospital, approximately 15% of patients with DLBCL were farmers, and the treatment failure rate of nonexposed patients was approximately 25%. We hypothesized a doubled treatment failure rate in pesticide-exposed patients. With use of a relative risk with a 2-sided α risk of 5% and a power of 80%, the number of patients required to meet significance was 238, of whom 34 would have been exposed to pesticides.

Statistical Analysis {#H2-11-ZOI190097}
--------------------

### Univariate Analysis of Confounding Factors {#H3-1-ZOI190097}

Confounding factors were compared according to pesticide exposure treatment failure by the χ^2^ test or Fisher exact test, as appropriate, for qualitative factors; the *t* test or Mann-Whitney test according to the distribution of the variables for quantitative factors, according to censored data (survival) by log-rank test for qualitative variables; and univariate Cox proportional hazards regression for discrete or continuous variables.

### Outcome Analysis {#H3-2-ZOI190097}

The treatment failure rate was compared between exposed and nonexposed patients using unconditional logistic regression, providing unadjusted odds ratios (ORs) and adjusted ORs (AORs) with 95% CIs (Wald test). Adjustment for known prognostic factors was systematically performed. Factors associated with treatment failure with a univariate *P* \< .20 were considered as potential confounding factors for multivariate analysis. For model building, we applied a change-in-estimate criterion, which involves looking separately at the OR compared with the AOR for each single variable. If the unadjusted and adjusted values differed by more than 10% (ie, AOR or OR \>1.1 or \<0.9), the variable was included in the multivariable model. The Hosmer-Lemeshow test was used to check the fit of the model.

The OS and EFS were described by Kaplan-Meier curves and compared between exposed and nonexposed patients by log-rank test and Cox proportional hazards regression model, providing unadjusted hazard ratios (HRs) and adjusted hazard ratios (AHRs) with 95% CIs (Wald test). Model building was made as described above. The OS was calculated from diagnosis to death (event data) or last date of follow-up (censored data). The EFS was calculated from diagnosis to first evidence of active disease under treatment or relapse (event data) or last date of follow-up without active disease (censored data).

SAS statistical software, version 9.4 (SAS Institute Inc) was used to perform all statistical analysis.

Results {#H1-3-ZOI190097}
=======

Participants {#H2-12-ZOI190097}
------------

In total, 244 patients (mean \[SD\] age, 61.3 \[15.2\] years; 153 \[62.7%\] male) were included and assessed for analysis, with a median length of follow-up of 33 months. A total of 945 patient files were screened. First inclusions were made in Montpellier, France, from January 1, 2010, to July 15, 2015. The rate of unreached patients before 2012 was greater than 60%; thus, for all other centers, patients diagnosed with non-Hodgkin nonfollicular lymphoma from January 1, 2012, to July 15, 2015, were screened: 404 met the inclusion criteria, of whom 282 were successfully contacted, with 38 refusing inclusion. Among the 122 unreached patients, 63 were confirmed to have died ([Figure 1](#zoi190097f1){ref-type="fig"}).

![Patient Flowchart\
Demographic data were missing for 50 patients. DLBCL indicates diffuse large B-cell lymphoma; HCV, hepatitis C virus.](jamanetwopen-2-e192093-g001){#zoi190097f1}

Comparison of characteristics between the included and not included (unreached or refusal to answer the job history interview) groups revealed a higher rate of unfavorable IPI in the not included group (44.3% vs 18.6%, *P* \< .001). Outcomes were worse in not included patients (treatment failure, 43.1% vs 14.3%, *P* \< .001). Two-year EFS was lower for not included patients (53.2% \[95% CI, 44.8%-60.9%\] vs 78.0% \[95% CI, 72.1%-82.8%\]) as was 2-year OS (60.1% \[95% CI, 51.7%-67.6%\] vs 89.8% \[95% CI, 85.1%-93.0%\]) (eTable 1 in the [Supplement](#note-ZOI190097-1-s){ref-type="supplementary-material"}). Among interview responders, 198 (81.1%) were patients and 46 (18.9%) were proxies.

Descriptive Data {#H2-13-ZOI190097}
----------------

The IPI was favorable for 83 patients (35.0%), intermediary I and II for 55 (23.2%) each, and unfavorable for 44 (18.6%); 35 patients (14.3% of 194 known status) were living alone, 151 (61.9%) were treated in teaching hospitals, and travel time to the hospital was less than 15 minutes for 37 patients (15.2%). The main treatment was rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for 214 patients (87.7%), mini-R-CHOP (reduced R-CHOP dosage) for 25 patients (10.2%), and doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone, and rituximab (R-ACVBP) for 5 (2%).

No difference in demographic characteristics, initial presentation, IPI, and treatment protocol between exposed and nonexposed patients was found; patients with no agricultural exposure were more likely to have disseminated disease (Ann Arbor stage IV) (104 \[50.5%\]) compared with patients with agricultural exposure (13 \[34.2%\]) (*P* = .05) ([Table 1](#zoi190097t1){ref-type="table"}).

###### Patient Characteristics by Exposure to Pesticides[^a^](#zoi190097t1n1){ref-type="table-fn"}

  Characteristic                                         Occupational Exposure (n = 67)   No Occupational Exposure (n = 177)   *P* Value   Exposing Agricultural Occupations (n = 38)   No Exposing Agricultural Occupations vs Others (n = 206)   *P* Value    High Probability of Occupational Exposure (n = 48)   No High Probability of Occupational Exposure (n = 196)   *P* Value   High Probability and Reliability of Occupational Exposure (n = 35)   No High Probability and Reliability of Occupational Exposure (n = 209)   *P* Value
  ------------------------------------------------------ -------------------------------- ------------------------------------ ----------- -------------------------------------------- ---------------------------------------------------------- ------------ ---------------------------------------------------- -------------------------------------------------------- ----------- -------------------------------------------------------------------- ------------------------------------------------------------------------ -----------
  Age, mean (SD), y                                      60.8 (15.8)                      61.4 (15.4)                          .77         64.3 (15.3)                                  60.7 (15.5)                                                .19          61.1 (16.7)                                          61.3 (15.2)                                              .92         63.5 (15.9)                                                          60.9 (15.4)                                                              .36
  Male                                                   44 (65.7)                        109 (61.6)                           .56         26 (68.4)                                    127 (61.6)                                                 .43          33 (68.8)                                            120 (61.2)                                               .33         22 (62.9)                                                            131 (62.7)                                                               .98
  Previous cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  No                                                     61 (91.0)                        152 (85.9)                           .55         34 (89.5)                                    179 (86.9)                                                 .83          44 (91.7)                                            169 (86.2)                                               .71         31 (88.6)                                                            182 (87.1)                                                               \>.99
  Treated with radiotherapy or chemotherapy              2 (3.0)                          9 (5.1)                              1 (2.6)     10 (4.6)                                     3 (6.2)                                                    17 (8.7)     3 (8.6)                                              17 (8.1)                                                                                                                                                                                                           
  Not treated with radiotherapy or chemotherapy          4 (6.0)                          16 (9.4)                             3 (7.9)     17 (8.3)                                     1 (2.1)                                                    10 (5.1)     1 (2.8)                                              10 (4.8)                                                                                                                                                                                                           
  ECOG score                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  No. of patients                                        64                               176                                              37                                           203                                                                     47                                                   193                                                                  35                                                                   205                                                                      
  0                                                      21 (32.8)                        57 (32.4)                            .75         11 (29.7)                                    67 (33.0)                                                  .60          14 (29.8)                                            64 (33.2)                                                .76         11 (31.4)                                                            67 (32.7)                                                                .79
  1                                                      25 (39.0)                        74 (42.0)                            14 (37.8)   85 (41.9)                                    19 (40.4)                                                  80 (41.4)    14 (40.0)                                            85 (41.5)                                                                                                                                                                                                          
  2                                                      11 (17.2)                        21 (11.9)                            8 (21.6)    24 (11.8)                                    9 (19.1)                                                   23 (11.9)    7 (20.0)                                             25 (12.2)                                                                                                                                                                                                          
  3                                                      5 (7.8)                          13 (7.4)                             2 (5.4)     16 (7.9)                                     3 (6.4)                                                    15 (7.8)     2 (5.7)                                              16 (7.8)                                                                                                                                                                                                           
  4                                                      2 (3.1)                          11 (6.2)                             2 (5.4)     11 (5.4)                                     2 (4.2)                                                    11 (5.7)     1 (2.9)                                              12 (5.8)                                                                                                                                                                                                           
  Ann Arbor staging,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  I                                                      22 (32.9)                        34 (19.2)                            .05         13 (34.2)                                    43 (20.9)                                                  .05          16 (33.3)                                            40 (20.4)                                                .14         10 (28.6)                                                            46 (22.0)                                                                .34
  II                                                     10 (14.9)                        30 (17.0)                            4 (10.5)    36 (17.5)                                    6 (12.5)                                                   34 (17.4)    5 (14.3)                                             35 (16.7)                                                                                                                                                                                                          
  III                                                    11 (16.4)                        20 (11.3)                            8 (21.1)    23 (11.2)                                    8 (16.7)                                                   23 (11.7)    7 (20.0)                                             24 (11.5)                                                                                                                                                                                                          
  IV                                                     24 (35.8)                        93 (52.5)                            13 (34.2)   104 (50.5)                                   18 (37.5)                                                  99 (50.5)    13 (37.1)                                            104 (49.8)                                                                                                                                                                                                         
  Determination                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Bone marrow                                            3 (4.5)                          19 (10.7)                            .13         1 (2.6)                                      21 (10.2)                                                  .22          2 (4.2)                                              20 (10.2)                                                .27         1 (2.9)                                                              21 (10.0)                                                                .22
  Central nervous system                                 0                                3 (1.7)                              .56         0                                            3 (1.5)                                                    1            0                                                    3 (1.5)                                                  1           0                                                                    3 (1.4)                                                                  1
  Lung                                                   6 (9.0)                          18 (10.2)                            .78         2 (5.3)                                      22 (10.7)                                                  .39          3 (6.3)                                              21 (10.7)                                                .43         1 (2.9)                                                              23 (11.0)                                                                .22
  Liver                                                  4 (6.0)                          19 (10.7)                            .26         4 (10.5)                                     19 (9.2)                                                   .77          4 (8.3)                                              19 (9.7)                                                 1           2 (5.7)                                                              21 (10.0)                                                                .55
  Gut                                                    3 (4.5)                          17 (9.6)                             .19         2 (5.3)                                      18 (8.7)                                                   .75          2 (42.2)                                             18 (9.2)                                                 .38         1 (2.9)                                                              19 (9.1)                                                                 .32
  B symptoms[^b^](#zoi190097t1n2){ref-type="table-fn"}   16 (23.9)                        43 (24.3)                            .95         7 (18.4)                                     52 (25.2)                                                  .37          10 (20.8)                                            49 (25.0)                                                .54         7 (20.0)                                                             52 (24.9)                                                                .53
  Bulky disease                                          14 (20.9)                        45 (25.4)                            .46         7 (18.4)                                     52 (25.2)                                                  .37          11 (22.9)                                            48 (24.5)                                                .82         6 (17.1)                                                             53 (25.4)                                                                .29
  LDH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  No. of patients                                        63                               171                                              36                                           198                                                                     45                                                   191                                                                  32                                                                   202                                                                      
  LDH greater than normal                                37 (58.7)                        98 (57.3)                            .85         21 (58.3)                                    114 (57.6)                                                 .92          27 (60.0)                                            108 (56.5)                                               .73         19 (59.4)                                                            116 (57.4)                                                               .84
  IPI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  No. of patients                                        63                               174                                              36                                           201                                                                     45                                                   192                                                                  32                                                                   205                                                                      
  Favorable (0-1)                                        24 (38.1)                        59 (33.9)                            .91         11 (30.6)                                    72 (35.8)                                                  .95          16 (35.5)                                            67 (34.9)                                                .68         10 (31.2)                                                            73 (35.6)                                                                .97
  Intermediary I (2)                                     14 (22.2)                        41 (23.6)                            9 (25.0)    46 (22.9)                                    8 (17.7)                                                   47 (24.5)    8 (25.0)                                             47 (22.9)                                                                                                                                                                                                          
  Intermediary II (3)                                    13 (20.6)                        42 (24.1)                            9 (25.0)    46 (22.9)                                    13 (28.9)                                                  42 (21.9)    8 (25.0)                                             47 (22.9)                                                                                                                                                                                                          
  Unfavorable (4-5)                                      12 (19.1)                        32 (18.3)                            7 (19.4)    37 (18.4)                                    8 (17.8)                                                   36 (18.7)    6 (18.8)                                             38 (18.5)                                                                                                                                                                                                          
  Transformation                                                                                                                                                                                                                                                                                                                                                              .                                                                                                                                                         
  No. of patients                                        63                               171                                              36                                           198                                                                     46                                                   188                                                                  34                                                                   200                                                                      
  From low-grade lymphoma                                8 (12.7)                         23 (13.5)                            .88         3 (8.3)                                      28 (14.1)                                                  .34          4 (8.7)                                              27 (14.4)                                                .31         4 (11.8)                                                             27 (13.5)                                                                \>.99
  Main treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  R-CHOP                                                 57 (85.1)                        157 (88.7)                           .60         31 (81.6)                                    183 (88.8)                                                 .13          40 (83.3)                                            174 (88.8)                                               .15         28 (80.0)                                                            185 (88.5)                                                               .13
  Mini-R-CHOP                                            9 (13.4)                         16 (9.0)                             7 (18.4)    18 (8.7)                                     8 (16.7)                                                   17 (8.7)     7 (20.0)                                             19 (9.1)                                                                                                                                                                                                           
  R-ACVBP                                                1 (1.5)                          4 (2.3)                              0           5 (2.4)                                      0                                                          5 (2.5)      0                                                    5 (2.4)                                                                                                                                                                                                            
  Teaching hospital                                      40 (59.7)                        111 (62.7)                           .67         21 (55.3)                                    130 (63.1)                                                 .36          29 (60.4)                                            122 (62.2)                                               .82         20 (57.1)                                                            131 (62.7)                                                               .53
  Marital status                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  No.                                                    54                               140                                              32                                           162                                                                     40                                                   154                                                                  28                                                                   166                                                                      
  Alone                                                  9 (16.7)                         26 (18.6)                            .76         4 (12.5)                                     31 (19.1)                                                  .37          6 (15.0)                                             29 (18.8)                                                .57         4 (14.3)                                                             31 (18.7)                                                                .58
  Travel time to reference hospital, min                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  ≤15                                                    8 (11.9)                         29 (16.4)                            .51         2 (5.3)                                      35 (17.0)                                                  .18          2 (4.2)                                              35 (17.9)                                                .02         2 (5.7)                                                              35 (16.8)                                                                .24
  16-44                                                  37 (55.2)                        101 (57.1)                           24 (63.2)   114 (55.3)                                   27 (56.2)                                                  111 (56.6)   22 (62.9)                                            116 (55.5)                                                                                                                                                                                                         
  ≥45                                                    22 (32.8)                        47 (26.5)                            12 (31.6)   57 (27.7)                                    19 (39.6)                                                  50 (25.5)    11 (31.4)                                            58 (27.8)                                                                                                                                                                                                          

Abbreviations: ECOG, European Cooperative Oncology Group; IPI, International Prognostic Index; LDH, lactate dehydrogenase; R-ACVBP, doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone, and rituximab; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.

Data are presented as number (percentage) of patients unless other wise indicated.

General symptoms, including fever, profuse sweats, and weight loss.

Among the 67 patients (27.4%) exposed to pesticides, 38 had occupational exposure from agriculture, 16 from green spaces maintenance, 15 from wood activities, and 11 from hygiene activities. Fifty-five patients had 1 source of exposure, 11 had 2 sources, and 1 had 3 sources.

Probabilities and duration of pesticide exposure among exposed patients, assessed by PESTIPOP, are given in eTable 2 in the [Supplement](#note-ZOI190097-1-s){ref-type="supplementary-material"}. Patients with agricultural occupations had nearly 100% probability of exposure. Patients with other exposing occupations had more variable probability of exposure.

Primary Outcome {#H2-14-ZOI190097}
---------------

Treatment failure occurred in 35 patients (14.3%), including toxicity-related death in 4 patients (1.6%). Two-year EFS was 78% (95% CI, 72%-83%), and 2-year OS was 90% (95% CI, 85%-93%). Mean (SD) age was 61.5 (15.0) years in the treatment failure group vs 61.2 (15.6) years in the treatment response group (*P* = .94). In univariate analysis, lung and liver determination, bulky disease, and IPI were significantly associated with treatment failure ([Table 2](#zoi190097t2){ref-type="table"}). Patients professionally exposed to pesticides had higher treatment failure rates compared with nonexposed patients (occupational exposure failure rate, 22.4% vs 11.3%; OR, 2.3; 95% CI, 1.1-4.7; *P* = .03; AOR for confounding factors, 3.0; 95% CI, 1.3-6.9). Patients with exposing agricultural occupations had a higher failure rate compared with others (29.0% vs 11.7%; OR, 3.1; 95% CI, 1.3-7.0; *P* = .005). Considering probability of exposure and reliability of PESTIPOP data, sensitivity analysis was performed. Patients with high probability of occupational exposure had a higher failure rate compared with others (25.0% vs 11.7%; OR, 2.5; 95% CI, 1.1-5.5; *P* = .02). Patients with high probability and reliability of occupational exposure had a higher failure rate compared with others (12.9% vs 22.9%; OR, 2.0; 95% CI, 0.8-4.9; *P* = .13). There was no statistical association between other exposing professions and treatment failure (3 \[20.0%\] wood exposed vs 32 \[14.0%\] not wood exposed, 3 \[18.8%\] green space exposed vs 32 \[14.0%\] not green space exposed, and 1 \[9.0%\] hygiene exposed vs 34 \[14.6%\] not hygiene exposed) ([Table 2](#zoi190097t2){ref-type="table"}).

###### Univariate and Multivariate Logistic Regression Analysis for Treatment Failure With Exposure to Pesticides[^a^](#zoi190097t2n1){ref-type="table-fn"}

  Characteristic                                                 Treatment Failure Rate, No./Total No. (%)   Univariate OR (95% CI)   *P* Value        Multivariate Occupational Exposure (Model 1), AOR (95% CI)[^b^](#zoi190097t2n2){ref-type="table-fn"}   *P* Value        Multivariate Exposing Agricultural Occupations (Model 2), AOR (95% CI)[^c^](#zoi190097t2n3){ref-type="table-fn"}   *P* Value       Multivariate High Probability of Occupational Exposure (Model 3), AOR (95% CI)[^d^](#zoi190097t2n4){ref-type="table-fn"}   *P* Value        Multivariate High Probability and Reliability of Occupational Exposure (Model 4) AOR (95% CI)[^e^](#zoi190097t2n5){ref-type="table-fn"}   *P* Value
  -------------------------------------------------------------- ------------------------------------------- ------------------------ ---------------- ------------------------------------------------------------------------------------------------------ ---------------- ------------------------------------------------------------------------------------------------------------------ --------------- -------------------------------------------------------------------------------------------------------------------------- ---------------- ----------------------------------------------------------------------------------------------------------------------------------------- -----------
  Sex                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Male                                                           19/153 (12.4)                               1 \[Reference\]          .27              NA                                                                                                     NA               NA                                                                                                                 NA              NA                                                                                                                         NA               NA                                                                                                                                        NA
  Female                                                         16/91 (17.6)                                1.5 (0.7-3.1)            NA               NA                                                                                                     NA               NA                                                                                                                 NA              NA                                                                                                                         NA               NA                                                                                                                                        
  Previous cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  No                                                             29/213 (13.6)                               1 \[Reference\]          .35              NA                                                                                                     NA               NA                                                                                                                 NA              NA                                                                                                                         NA               NA                                                                                                                                        NA
  Treated with radiotherapy or chemotherapy                      5/20 (25.0)                                 2.1 (0.7-6.3)            NA               NA                                                                                                     NA               NA                                                                                                                 NA              NA                                                                                                                         NA               NA                                                                                                                                        
  Not treated with radiotherapy or chemotherapy                  1/11 (9.1)                                  0.6 (0.1-5.1)            NA               NA                                                                                                     NA               NA                                                                                                                 NA              NA                                                                                                                         NA               NA                                                                                                                                        
  Determination                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  No bone marrow                                                 32/222 (14.4)                               1 \[Reference\]          .92              NA                                                                                                     NA               NA                                                                                                                 NA              NA                                                                                                                         NA               NA                                                                                                                                        NA
  Bone marrow                                                    3/22 (13.6)                                 1.1 (0.3-3.8)            NA               NA                                                                                                     NA               NA                                                                                                                 NA              NA                                                                                                                         NA               NA                                                                                                                                        
  No CNS                                                         35/241 (14.5)                               1 \[Reference\]          .99              NA                                                                                                     NA               NA                                                                                                                 NA              NA                                                                                                                         NA               NA                                                                                                                                        NA
  CNS                                                            0/3                                         NA                       NA               NA                                                                                                     NA               NA                                                                                                                 NA              NA                                                                                                                         NA               NA                                                                                                                                        
  No lung                                                        27/220 (12.3)                               1 \[Reference\]          .008             NA                                                                                                     .04              1 \[Reference\]                                                                                                    .05             1 \[Reference\]                                                                                                            .05              1 \[Reference\]                                                                                                                           .04
  Lung                                                           8/24 (33.3)                                 3.6 (1.4-9.1)            NA               3.0 (1.0-8.7)                                                                                          3.0 (1.0-8.6)    3.3 (1.1-9.5)                                                                                                                                                                                                                                                                                                                                                                                                            
  No liver                                                       27/221 (12.2)                               1 \[Reference\]          .006             1 \[Reference\]                                                                                        .03              NA                                                                                                                 NA              NA                                                                                                                         NA               1 \[Reference\]                                                                                                                           .05
  Liver                                                          8/23 (34.8)                                 3.8 (1.5-9.9)            3.0 (1.0-8.7)    NA                                                                                                     NA               NA                                                                                                                 NA              3.1 (1.0-9.1)                                                                                                                                                                                                                                                                         
  No gut                                                         34/224 (15.2)                               1 \[Reference\]          .24              NA                                                                                                     NA               NA                                                                                                                 NA              NA                                                                                                                         NA               NA                                                                                                                                        NA
  Gut                                                            1/20 (5.0)                                  0.3 (0.0-2.3)            NA               NA                                                                                                     NA               NA                                                                                                                 NA              NA                                                                                                                         NA               NA                                                                                                                                        
  Bulky disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  No                                                             21/185 (11.3)                               1 \[Reference\]          .02              NA                                                                                                     NA               1 \[Reference\]                                                                                                    .09             NA                                                                                                                         NA               1 \[Reference\]                                                                                                                           .14
  Yes                                                            14/59 (23.7)                                2.4 (1.2-5.2)            NA               NA                                                                                                     2.1 (0.9-5.0)    NA                                                                                                                 NA              1.9 (0.8-4.5)                                                                                                                                                                                                                                                                         
  IPI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Favorable and intermediary I (0-2)                             9/138 (6.5)                                 1 \[Reference\]          .001             1 \[Reference\]                                                                                        .02              1 \[Reference\]                                                                                                    .02             1 \[Reference\]                                                                                                            .02              1 \[Reference\]                                                                                                                           .02
  Intermediary II (3)                                            11/55 (20.0)                                3.6 (1.4-9.2)            3.1 (1.2-8.6)    3.0 (1.1-8.2)                                                                                          3.1 (1.2-8.3)    2.4 (0.9-6.8)                                                                                                                                                                                                                                                                                                                                                                                                            
  Unfavorable (4-5)                                              12/44 (27.3)                                5.4 (2.1-13.9)           4.4 (1.6-12.2)   4.0 (1.4-11.2)                                                                                         4.3 (1.6-12.0)   3.0 (1.0-8.6)                                                                                                                                                                                                                                                                                                                                                                                                            
  Teaching hospital                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Yes                                                            22/151 (14.6)                               1 \[Reference\]          .90              NA                                                                                                     NA               NA                                                                                                                 NA              NA                                                                                                                         NA               NA                                                                                                                                        NA
  No                                                             13/93 (14.0)                                1.0 (0.5-2.0)            NA               NA                                                                                                     NA               NA                                                                                                                 NA              NA                                                                                                                         NA               NA                                                                                                                                        
  Marital status                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Not alone                                                      22/159 (13.8)                               1                        .36              NA                                                                                                     NA               NA                                                                                                                 NA              NA                                                                                                                         NA               NA                                                                                                                                        NA
  Alone                                                          7/35 (20.0)                                 1.6 (0.6-4.0)            NA               NA                                                                                                     NA               NA                                                                                                                 NA              NA                                                                                                                         NA               NA                                                                                                                                        
  Unknown                                                        50                                          NA                       NA               NA                                                                                                     NA               NA                                                                                                                 NA              NA                                                                                                                         NA               NA                                                                                                                                        
  Travel time to hospital, min                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  ≤15                                                            2/37 (5.4)                                  1                        .26              NA                                                                                                     NA               NA                                                                                                                 NA              NA                                                                                                                         NA               NA                                                                                                                                        NA
  16-44                                                          21/138 (15.2)                               3.1 (0.7-14.1)           NA               NA                                                                                                     NA               NA                                                                                                                 NA              NA                                                                                                                         NA               NA                                                                                                                                        
  ≥45                                                            12/69 (17.4)                                3.7 (0.8-17.5)           NA               NA                                                                                                     NA               NA                                                                                                                 NA              NA                                                                                                                         NA               NA                                                                                                                                        
  Pesticide exposure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  No exposed occupation                                          20/177 (11.3)                               1 \[Reference\]          .03              1 \[Reference\]                                                                                        .009             NA                                                                                                                 NA              NA                                                                                                                         NA               NA                                                                                                                                        NA
  All exposed occupation                                         15/67 (22.4)                                2.3 (1.1-4.7)            3.0 (1.3-6.9)    NA                                                                                                     NA               NA                                                                                                                 NA              NA                                                                                                                         NA                                                                                                                                                         
  No exposing agricultural occupations                           24/206 (11.7)                               1 \[Reference\]          .005             NA                                                                                                     NA               1 \[Reference\]                                                                                                    .001            NA                                                                                                                         NA               NA                                                                                                                                        NA
  Exposing agricultural occupations                              11/38 (29.0)                                3.1 (1.3-7.0)            NA               NA                                                                                                     5.1 (2.0-12.8)   NA                                                                                                                 NA              NA                                                                                                                         NA                                                                                                                                                         
  No wood exposure                                               32/229 (14.0)                               1 \[Reference\]          .46              NA                                                                                                     NA               NA                                                                                                                 NA              NA                                                                                                                         NA               NA                                                                                                                                        NA
  Wood exposure                                                  3/15 (20.0)                                 1.5 (0.4-5.8)            NA               NA                                                                                                     NA               NA                                                                                                                 NA              NA                                                                                                                         NA               NA                                                                                                                                        
  No green spaces exposure                                       32/228 (14.0)                               1 \[Reference\]          .71              NA                                                                                                     NA               NA                                                                                                                 NA              NA                                                                                                                         NA               NA                                                                                                                                        NA
  Green spaces exposure                                          3/16 (18.8)                                 1.4 (0.4-5.2)            NA               NA                                                                                                     NA               NA                                                                                                                 NA              NA                                                                                                                         NA               NA                                                                                                                                        
  No hygiene exposure                                            34/233 (14.6)                               1 \[Reference\]          \>.99            NA                                                                                                     NA               NA                                                                                                                 NA              NA                                                                                                                         NA               NA                                                                                                                                        NA
  Hygiene exposure                                               1/11 (9.0)                                  0.6 (0.1-4.7)            NA               NA                                                                                                     NA               NA                                                                                                                 NA              NA                                                                                                                         NA               NA                                                                                                                                        
  No high probability of occupational exposure                   23/196 (11.7)                               1 \[Reference\]          .02              NA                                                                                                     NA               NA                                                                                                                 NA              1 \[Reference\]                                                                                                            .005             NA                                                                                                                                        NA
  High probability of occupational exposure                      12/48 (25.0)                                2.5 (1.1-5.5)            NA               NA                                                                                                     NA               NA                                                                                                                 3.6 (1.5-8.5)   NA                                                                                                                         NA               NA                                                                                                                                        
  No high probability and reliability of occupational exposure   27/209 (12.9)                               1 \[Reference\]          .13              NA                                                                                                     NA               NA                                                                                                                 NA              NA                                                                                                                         NA               1 \[Reference\]                                                                                                                           .02
  High probability and reliability of occupational exposure      8/35 (22.9)                                 2.0 (0.8-4.9)            NA               NA                                                                                                     NA               NA                                                                                                                 NA              NA                                                                                                                         3.7 (1.4-10.1)   NA                                                                                                                                        

Abbreviations: AOR, adjusted odds ratio; CNS, central nervous system; IPI, International Prognostic Index; NA, not applicable; OR, odds ratio.

For multivariate model, the sample size is 237 because of missing data for IPI in 7 patients.

Multivariate model 1 included variables: occupational exposure, IPI, and liver and lung determination. Hosmer-Lemeshow test, *P* \> .99.

Multivariate model 2 included exposing agricultural occupations, IPI, lung determination, and bulky disease. Hosmer-Lemeshow test, *P* = .52.

Multivariate model 3 included high probability of occupational exposure, IPI, and lung determination. Hosmer-Lemeshow test, *P* = .74.

Multivariate model 4 included high probability and reliability of occupational exposure, IPI, liver and lung determination, and bulky disease. Hosmer-Lemeshow test, *P* = .84.

In multivariate analysis ([Table 2](#zoi190097t2){ref-type="table"}), occupational exposure to pesticides remained independently associated with treatment failure (all occupational exposure vs no occupational exposure \[model 1\]: AOR, 3.0; 95% CI, 1.4-6.9; *P* = .009; exposing agricultural occupations vs others \[model 2\]: AOR, 5.1; 95% CI, 2.0-12.8; *P* = .001; high probability of occupational exposure vs others \[model 3\]: AOR, 3.6; 95% CI, 1.5-8.5; *P* = .005; high probability and reliability of occupational exposure vs others \[model 4\]: AOR, 3.7; 95% CI, 1.4-10.1; *P* = .02) ([Table 2](#zoi190097t2){ref-type="table"}).

The probabilities and duration of exposure among exposed patients according to treatment response are given in eTable 2 in the [Supplement](#note-ZOI190097-1-s){ref-type="supplementary-material"}.

Secondary Outcomes {#H2-15-ZOI190097}
------------------

### Event-Free Survival {#H3-3-ZOI190097}

In univariate analysis, unfavorable IPI, liver determination, lung determination, bulky disease, occupational exposure ([Table 3](#zoi190097t3){ref-type="table"}), exposing agricultural occupation, and high probability and reliability of occupational exposure ([Table 3](#zoi190097t3){ref-type="table"} and [Figure 2](#zoi190097f2){ref-type="fig"}) were statistically associated with poorer EFS. Two-year event-free survival was 70% in the occupational exposed group vs 82% in the unexposed group (*P* = .04); among patients with exposing agricultural occupations compared with other patients, the difference was more pronounced (56% vs 83%; *P* = .002). In multivariate analysis, occupational exposure was associated with reduced EFS (all occupational exposure vs others: AHR, 2.2; 95% CI, 1.3-3.9; *P* = .005 \[adjustment for IPI and liver determination\]; agricultural occupations vs nonagricultural occupations: AHR, 3.5; 95% CI, 1.9-6.5; *P* \< .001 \[adjustment for IPI and lung determination\]; high probability of occupational exposure vs others: AHR, 2.7; 95% CI, 1.5-4.9; *P* \< .001 \[adjustment for IPI and lung determination\]; high probability and reliability of occupational exposure vs others: AHR, 2.6; 95% CI, 1.3-5.0; *P* = .006 \[adjustment for IPI, liver, and lung determination\]).

###### Univariate Cox Proportional Hazards Regression Analysis for Overall Survival and Event-Free Survival With Known Risk Factors and Exposure to Pesticides

  Characteristic                                                 2-y Survival       2-y Event-Free Survival                                                           
  -------------------------------------------------------------- ------------------ ------------------------- ------------------ ------------------ ----------------- --------
  Determination                                                                                                                                                       
  No lung                                                        0.93 (0.88-0.95)   1 \[Reference\]           .002               0.81 (0.75-0.85)   1 \[Reference\]   .02
  Lung                                                           0.71 (0.48-0.85)   3.9 (1.6-9.3)             0.58 (0.36-0.75)   2.4 (1.2-4.8)                        
  No liver                                                       0.92 (0.88-0.95)   1 \[Reference\]           .007               0.80 (0.74-0.85)   1 \[Reference\]   .006
  Liver                                                          0.74 (0.51-0.87)   3.5 (1.4-8.8)             0.61 (0.38-0.77)   2.6 (1.3-5.2)                        
  Bulky disease                                                                                                                                                       
  No                                                             0.91 (0.86-0.94)   1 \[Reference\]           .70                0.82 (0.75-0.87)   1 \[Reference\]   .02
  Yes                                                            0.88 (0.76-0.94)   1.2 (0.5-2.8)             0.69 (0.55-0.79)   1.9 (1.1-3.3)                        
  IPI                                                                                                                                                                 
  Favorable and intermediary I (0-2)                             0.98 (0.93-0.99)   1 \[Reference\]           .001               0.90 (0.83-0.94)   1 \[Reference\]   \<.001
  Intermediary II (3)                                            0.89 (0.77-0.95)   4.8 (1.4-16.3)            0.68 (0.53-0.79)   4.6 (2.4-9.0)                        
  Unfavorable (4-5)                                              0.72 (0.56-0.83)   12.6 (4.1-38.7)           0.60 (0.44-0.73)   5.6 (2.8-11.3)                       
  Pesticide exposure                                                                                                                                                  
  No exposed occupation                                          0.92 (0.87-0.95)   1 \[Reference\]           .33                0.82 (0.75-0.87)   1 \[Reference\]   .04
  All exposed occupation                                         0.86 (0.75-0.93)   1.5 (0.7-3.4)             0.70 (0.57-0.79)   1.8 (1.0-3.0)                        
  No exposing agricultural occupations                           0.92 (0.87-0.95)   1 \[Reference\]           .07                0.83 (0.77-0.87)   1 \[Reference\]   .002
  Exposing agricultural occupations                              0.81 (0.65-0.91)   2.3 (0.9-5.3)             0.56 (0.38-0.70)   2.5 (1.4-4.4)                        
  No high probability of occupational exposure                   0.92 (0.87-0.95)   1 \[Reference\]           .26                0.82 (0.76-0.87)   1 \[Reference\]   .009
  High probability of occupational exposure                      0.85 (0.72-0.93)   1.7 (0.7-4.0)             0.63 (0.48-0.76)   2.1 (1.2-3.7)                        
  No high probability and reliability of occupational exposure   0.91 (0.86-0.94)   1 \[Reference\]           .75                0.81 (0.75-0.86)   1 \[Reference\]   .08
  High probability and reliability of occupational exposure      0.90 (0.85-0.93)   1.2 (0.4-3.5)             0.64 (0.45-0.78)   1.8 (0.9-3.6)                        

Abbreviations: HR, hazard ratio; IPI, International Prognostic Index.

![Event-Free and Overall Survival](jamanetwopen-2-e192093-g002){#zoi190097f2}

### Overall Survival {#H3-4-ZOI190097}

In univariate analysis, unfavorable IPI, liver determination, and lung determination were associated with poorer OS ([Table 3](#zoi190097t3){ref-type="table"}); no pesticide exposure was associated with poorer OS ([Table 3](#zoi190097t3){ref-type="table"} and [Figure 2](#zoi190097f2){ref-type="fig"}). Overall survival was 81% in the agricultural exposed group vs 92% in the non--agricultural exposed group, *P* = .07. In multivariate analysis, occupational exposure was associated with reduced OS for exposed agricultural occupations vs all others (AHR, 3.9; 95% CI, 1.5-10.0; *P* \< .001 \[adjustment for IPI and lung determination\]) but was not associated with reduced OS for high probability of occupational exposure vs all others (AHR, 2.4; 95% CI, 1.0-5.8; *P* = .06 \[adjustment for IPI and lung determination\]), all occupational exposure vs others (AHR, 1.8; 95% CI, 0.7-4.1; *P* = .19 \[adjustment for IPI, liver determination\]), or high probability and reliability of occupational exposure vs others (AHR, 2.1; 95% CI, 0.7-6.6; *P* = .19 \[adjustment for IPI, liver, and lung determination\]).

Sensitivity Analysis {#H2-16-ZOI190097}
--------------------

We performed a sensitivity analysis to examine the association of responder (patient or proxy), and the association was slightly increased in the subgroup of patient responders (n = 194, with 4 missing data for IPI) compared with the total population (eTable 3 in the [Supplement](#note-ZOI190097-1-s){ref-type="supplementary-material"}). Multivariate analysis in the subgroup of proxy responders was not performed because of low size of sample (n = 44, with 3 missing data for IPI).

Discussion {#H1-4-ZOI190097}
==========

The results of this study suggest that the prognosis of DLBCL in terms of treatment failure and survival is statistically associated with a history of occupational exposure to pesticides, notably from agricultural occupations. Outcomes in our selected population and phase 3 study population are similar.^[@zoi190097r27],[@zoi190097r28]^ Analysis of all preselected patients showed similar outcomes to those published in the real-life study for the use of R-CHOP to treat DLBCL.^[@zoi190097r12]^ Contrary to the work of Le Guyader-Peyrou et al,^[@zoi190097r24]^ we found no association between prognosis and living-alone status, travel time to hospital, and treatment in nonteaching hospitals, probably because of our study's smaller sample size. There was a higher rate of an earlier stage at diagnosis among pesticide-exposed patients, which is traditionally associated with better prognosis (part of the IPI) and could bias the outcome; this variable was included in the multivariate model. The use of a JEM, which is more sensitive and less specific than job exposure modules based on specific tasks, is likely to attenuate the OR.^[@zoi190097r29]^ We performed 4 analyses using JEM probability and reliability threshold for occupational exposure. The first analysis included all patients with low or high probability of exposure; another analysis considered only agricultural exposure, which is the better known according to the literature; another analysis considered high probability (\>75%); and the last one considered high probability and reliability. There was an increasing gradient between the AOR for treatment failure for all probability of exposure (AOR, 3.0; 95% CI, 1.3-7.0), high probability (AOR, 3.6; 95% CI, 1.5-8.5) and high probability and reliability of exposure (AOR, 3.7; 95% CI, 1.4-10.1), and exposing agricultural occupations (AOR, 5.1; 95% CI, 2.0-12.8). This finding suggests that resistance to treatment could be provided by specific agents used in farming activities.

Standard treatment for DLBCL is 6 to 8 courses of R-CHOP, and interim response assessment after 4 courses has been found to be indicative of survival,^[@zoi190097r30]^ leading to treatment change for patients not reaching complete response. Thus, response after 4 courses could be considered as a surrogate of chemosensitivity. No central assessment of response had been made in this retrospective study, and less than 5% of patients had computed tomographic evaluation, which could induce misclassification of incomplete responses. However, this bias seems to be limited because 2-year EFS produced similar results to treatment response.

Limitations {#H2-17-ZOI190097}
-----------

Gene expression profiling has highlighted 2 groups of DLBCL: germinal center derived, with good prognosis, or activated B-cell derived.^[@zoi190097r11]^ However, neither gene expression, germinal center, nor activated B-cell immunophenotyping was systematically performed in this study, and we could not evaluate the relationship between pesticide exposure and cell of origin.

Occupational history could only be assessed for 60.4% of the patients treated for DLBCL, mostly because of the high rate of deceased patients; thus, the reachable patients had a better prognosis, potentially overestimating or underestimating the adverse prognosis of occupational exposure to pesticides. Likewise, some interview responders are proxies, mostly because of deceased patients, with a worse outcome. We performed a sensitivity analysis on the patient responder subgroup, excluding proxy responders. The ORs were slightly increased among the patient responder subgroup. Selection and nondifferential misclassification bias are possible.

Retrospective occupational exposure assessment is difficult and leads to potential misclassification bias. Use of the PESTIPOP reduces nondifferential misclassification because of its high reproducibility.

PESTIPOP does not consider the nonprofessional intensive use of pesticides, sometimes spontaneously described by patients during the interview (eg, undeclared work on a family farm). Likewise, this study ignores exposure shorter than 1 year. However, JEMs are often the best way to estimate long-term exposures, especially in retrospective surveys when individuals are unable to remember or are unaware of past exposures.^[@zoi190097r31]^ The association of professional exposure to pesticides with prognosis was stronger among patients with exposing agricultural occupations: the difference of response rate was higher than when considering all exposed patients, and the OR was higher. Pesticides exposure for other occupations based on PESTIPOP may be misclassifying unexposed as exposed because of the lack of pieces of information on specific tasks performed within the same jobs. In our study, no difference was found between short- and long-term exposure, but a patient sample of long-term exposed patients was small. We used logistic regression for response to immunochemotherapy, which estimates the relative risk with the OR, thus overestimating the relative risks. However, the estimated HRs for EFS analysis remained significant.

Another limitation was the consideration of pesticides as a cocktail of all different insecticides, fungicides, and herbicides used in farming, wood, hygiene, or green space activities as 1 homogeneous exposure for 40 years. Many different agents have been used, and another analysis of the results with PESTIMAT^[@zoi190097r32]^ could give more precise details on the effects of single agents.

Conclusions {#H1-5-ZOI190097}
===========

This study suggests for the first time, to our knowledge, a poorer prognosis for patients with DLBCL exposed to pesticides, concerning the response to treatment, 2-year EFS, and OS. These findings must be confirmed in further prospective studies. The biology of these tumors and characterization of specific pesticides should also be studied.

###### 

**eAppendix.** Method for Matrix Generation

**eTable 1.** Table of Comparison for Included and Not Included (Unreached or Refusal) Patients

**eTable 2.** Table of Description of Pesticide Exposure Among Complete Response or Treatment Failure Exposed Patients

**eTable 3.** Sensitivity Analysis: Subgroup of Patient Interview Responders
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Click here for additional data file.
